可孚医疗科技股份有限公司 关于董事会完成换届选举及聘任高级管理 人员、证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）于 2026 年 1 月 16 日召开 2026 年第一次临时股东会，审议通过了《关于公司董事会换届选举暨提名第三 届董事会非独立董事候选人的议案》《关于公司董事会换届选举暨提名第三届董 事会独立董事候选人的议案》，选举产生公司第三届董事会非职工代表董事，与 公司职工代表大会选举产生的职工代表董事共同组成公司第三届董事会，完成董 事会换届选举。同日，公司召开第三届董事会第一次会议，选举产生了公司董事 长、副董事长、各专门委员会成员，并聘任了新一届高级管理人员、证券事务代 表。现将有关情况公告如下： 一、公司第三届董事会及董事会各专门委员会组成情况 （一）董事会成员 1、非独立董事：张敏先生（董事长）、张志明先生（副董事长）、薛小桥 先生 证券代码：301087 证券简称：可孚医疗 公告编号：2026-013 1 提名委员会：宁华波先生（召集人）、贺邦杰先生、沈楠女士 薪酬与考核委员 ...

关于 可孚医疗科技股份有限公司 2026年第一次临时股东会的 法律意见书 湖南启元律师事务所 二零二六年一月 1 致：可孚医疗科技股份有限公司 湖南启元律师事务所（以下简称"本所"）接受可孚医疗科技股份有限公司（以 下简称"公司"）的委托，指派本所律师出席了公司 2026 年第一次临时股东会（以 下简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人员及召集 人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表本法律 意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华 人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》（以下 简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《可孚医疗科 技股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具本法律意见 书。 本所律师声明如下： 为发表本法律意见，本所律师依法查验了公司提供的下列资料： 1、刊登在深圳证券交易所网站（https://www.szse.cn/）的与本次股东会有关 的通知等公告事项； 2、出席会议的股东或其代理人的身份证明文件、持股证明文件、授权委托书 等； 3、本次 ...

第三届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 可孚医疗科技股份有限公司（以下简称"公司"）第三届董事会第一次会议 经全体董事一致同意豁免会议通知期限要求，现场发出会议通知，于 2026 年 1 月 16 日在公司八楼会议室以现场方式召开。会议应出席董事 7 名，实际出席董 事 7 人，公司高级管理人员列席会议。本次会议由董事张敏先生主持。会议的召 集和召开符合《中华人民共和国公司法》等法律法规和《公司章程》的有关规定。 证券代码：301087 证券简称：可孚医疗 公告编号：2026-012 可孚医疗科技股份有限公司 二、董事会会议审议情况 与会董事对本次会议需审议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过了《关于选举公司第三届董事会董事长、副董事长的议案》 公司董事会选举公司第三届董事会董事长、副董事长，任期三年，自本次会 议审议通过之日起至第三届董事会任期届满之日止。 （1）选举张敏先生为公司第三届董事会董事长 表决结果：同意 7 票，反对 0 票，弃权 0 票。 （2）选举张志明先生为公司第 ...

Group 1 - The construction of a "super factory" by Brain Tiger Technology in Jiangxi marks a significant transition from laboratory research to large-scale production in the brain-computer interface (BCI) sector, aiming for stable supply of tens of thousands of units [1][6] - The factory will produce China's first and the world's second fully implanted, fully wireless, and fully functional BCI system, highlighting the growing market potential across healthcare, consumer electronics, and military applications [1][6] - Global developments include Neuralink's announcement to start large-scale production of BCI devices by 2026, indicating a shift from clinical validation to industrialization [1][6] Group 2 - The Chinese government is actively promoting the BCI industry, with a policy document aiming for breakthroughs in key technologies by 2027 and a robust industry system by 2030 [2][7] - The "14th Five-Year Plan" identifies BCI as a future industry requiring strategic development, with various regions setting clear goals for BCI technology and product applications [2][7] - Successful surgeries have been performed on high-level paraplegics using BCI technology, enabling patients to control devices and participate in rehabilitation and employment activities [2][7] Group 3 - The BCI sector has attracted significant investment, with the A-share market showing a cumulative increase of over 20% since 2026, and several stocks rising more than 50% [3][8] - As of January 13, 2023, the financing balance for 26 BCI-related stocks reached nearly 25.5 billion yuan, a 15% increase from the previous year, with many stocks seeing substantial increases in their financing [3][8] - Notable companies include Meihua Medical, with a financing balance of 470 million yuan and a 255% increase, and Innovation Medical, with a balance of 744 million yuan and a 105% increase [3][8][9]

Group 1 - The core point of the article highlights the significant advancements in the brain-computer interface (BCI) industry, particularly with the construction of Brain Tiger Technology's "super factory" in Jiangxi, which marks a transition from laboratory research to large-scale production of BCI systems [3] - The factory aims to produce the first domestically developed and the world's second fully implanted, wireless, and fully functional BCI system, targeting stable supply of tens of thousands of units [3] - The BCI technology shows immense potential across various sectors, including healthcare, consumer electronics, and military aerospace, with significant developments occurring globally [3] Group 2 - The Chinese government is actively promoting the BCI industry, with a policy document issued in July 2025 outlining goals for technological breakthroughs and the establishment of a robust industry framework by 2030 [4] - The market for BCIs is projected to grow significantly, with global market size expected to reach approximately $2.62 billion in 2024 and $12.4 billion by 2034, while China's market is anticipated to grow from 3.2 billion yuan in 2024 to 5.58 billion yuan by 2027, reflecting a compound annual growth rate of about 20% [4] Group 3 - The BCI sector has attracted substantial investment, with the A-share market seeing a cumulative increase of over 20% in the BCI theme index since 2026, and several stocks experiencing gains exceeding 50% [5] - As of January 13, 2023, 19 out of 26 BCI concept stocks were eligible for margin trading, with a total financing balance of nearly 25.5 billion yuan, an increase of over 15% compared to the end of the previous year [5] - Notable companies such as Meihua Medical and Innovation Medical have seen significant increases in their financing balances, indicating strong investor interest and strategic partnerships in the BCI field [5][6]

Core Viewpoint - The stock of Kefu Medical (301087) has shown a slight decline, with a closing price of 59.5 yuan on January 14, 2026, down by 1.65% [1] Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, an increase of 6.63% year-on-year [2] - The net profit attributable to the parent company was 260 million yuan, up by 3.3% year-on-year [2] - The net profit after deducting non-recurring items was 222 million yuan, reflecting a year-on-year increase of 1.46% [2] - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, a significant increase of 30.72% year-on-year [2] - The single-quarter net profit attributable to the parent company was approximately 92.83 million yuan, up by 38.68% year-on-year [2] - The single-quarter net profit after deducting non-recurring items was 85.80 million yuan, marking a year-on-year increase of 62.68% [2] - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan [2] - The gross profit margin is reported at 53.35% [2] Market Activity - On January 14, 2026, the net outflow of main funds was 23.53 million yuan, accounting for 3.54% of the total transaction amount [1] - Retail investors saw a net inflow of 17.96 million yuan, representing 2.7% of the total transaction amount [1] - Over the past 90 days, 8 institutions have provided ratings for Kefu Medical, with 7 buy ratings and 1 hold rating [2] - The average target price set by institutions in the last 90 days is 545.6 million yuan [2]

Group 1 - The A-share market showed mixed performance with the Shanghai Composite Index down by 0.31%, while the Shenzhen Component Index and the ChiNext Index rose by 0.56% and 0.82% respectively [1] - The total trading volume reached a record high of 3.99 trillion yuan, surpassing the previous day's 3.66 trillion yuan, indicating strong market participation and enthusiasm [1] - The increase in trading volume is attributed to significant inflows of capital from domestic and foreign investment institutions and individual investors [1] Group 2 - In the Hunan stock market, less than half of the stocks saw price increases, with notable gainers including Changlan Technology and Heshun Petroleum, both rising over 10% [2] - The commercial aerospace sector remained sluggish, with stocks like Shaoyang Hydraulic and Hualing Cable experiencing declines of 9.64% and 5.58% respectively [2] - Other sectors such as medical services, biopharmaceuticals, and chemical pharmaceuticals also showed low activity, with companies like Erkang Pharmaceutical and Huana Pharmaceutical both down by 3.19% [2]

Core Viewpoint - Kefu Medical (301087) is focusing on strategic collaborations with companies specializing in advanced brain-machine interface technologies to enhance its existing rehabilitation and respiratory product lines [1] Group 1: Company Developments - Kefu Medical has engaged in strategic cooperation with NeuLink Medical, which is dedicated to invasive brain-machine interface technology, currently developing bionic ear and bionic eye products in the early research phase [1] - The collaboration aims to integrate cutting-edge brain-machine interface technologies with Kefu Medical's existing product lines, fostering strategic synergy [1] Group 2: Product and Technology Insights - NeuLink Medical's products are designed to provide innovative solutions for patients with hearing and vision impairments [1] - Lizi Intelligent has successfully implemented multimodal brain-controlled rehabilitation robots for large-scale clinical applications targeting central nervous system injuries, with over 20 products developed, 7 of which have been approved for market [1] - The company will continue to monitor the progress of these collaborations and actively promote the development and implementation of related joint research projects and product solutions [1]

Group 1 - The core viewpoint of the article is that Kefu Medical (301087) is strategically investing in the brain-computer interface sector and has formed a partnership with the invested company, Lizi Intelligent, to jointly develop collaborative products such as ventilators and EEG sleep monitors [1]

Group 1 - The stock price of Kefu Medical reached a historical high, increasing by 6.17% to 62.96 yuan, with a trading volume of 5.5943 million shares and a transaction value of 327 million yuan, resulting in a turnover rate of 2.88% [2] - The latest total market capitalization of Kefu Medical in A-shares is 13.152 billion yuan, with a circulating market value of 12.230 billion yuan [2] - The pharmaceutical and biotechnology industry, to which Kefu Medical belongs, has an overall increase of 2.36%, with 446 stocks rising and 16 stocks hitting the daily limit [2] Group 2 - The latest margin trading data shows that Kefu Medical has a margin balance of 195 million yuan, with a financing balance of 193 million yuan, which has increased by 94.669 million yuan over the past 10 days, representing a growth of 96.75% [2] - According to the company's Q3 report, Kefu Medical achieved an operating income of 2.398 billion yuan in the first three quarters, a year-on-year increase of 6.63%, and a net profit of 260 million yuan, a year-on-year increase of 3.30% [2] - The basic earnings per share for Kefu Medical is 1.2800 yuan, with a weighted average return on net assets of 5.29% [2]